A review of the data from phase 3 randomized Phase 3 Study of 177Lu-PSMA-617 or best supportive/standard of care, VISION, in the treatment of patients with progressive PSMA-positive mCRPC and Dr. Morgans’ experience with 177Lu-PSMA-617.
Videos
Dr. Morgans talks about available second-line treatment options for patients with mCRPC and considerations when choosing second and subsequent-line treatment options.
An overview of how patients with mCRPC are monitored and followed-up in practice and the triggers to reevaluate the treatment patient is receiving.
Unmet needs and future directions in the prevention and management of chemotherapy-induced neutropenia.
Dr. Morgans discusses first-line therapy options for mCRPC and her approach to deciding between different treatment options.
A discussion regarding patient selection and indications for using plinabulin, a first-in-class selective immunomodulating microtubule-binding agent, as prophylaxis against chemotherapy-induced neutropenia.
Alicia Morgans, MD, MPH presents the case of a 70-year-old man with progressive PSMA-positive mCRPC.
Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, consider potential treatment options for relapsed/refractory diffuse large B-cell lymphoma in the future.
Two experts examine bispecific antibody treatment use for relapsed/refractory diffuse large B-cell lymphoma.
Lori Wirth, MD, discusses the mechanism of action of pralsetinib and key data from the phase 1/2 ARROW clinical trial.
The panel of experts discuss practical considerations regarding selpercatinib and the LIBRETTO-001 and LIBRETTO-531 clinical trial data.
Lori Wirth, MD, discusses the mechanism of action of selpercatinib and key data from the LIBRETTO-001 and LIBRETTO-531 clinical trials.
Experts in the management of thyroid cancer share their treatment recommendations for a 60-year-old man with RET+ metastatic medullary thyroid cancer.
The panel of experts discuss the importance of molecular testing and RET mutations in thyroid cancer disease management.
Dr Wirth reviews disease management considerations a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Lori Wirth, MD, and Andrew Gianoukakis, MD, discuss patient and clinical characteristics necessitating thyroidectomy in patients with thyroid cancer.
Lori Wirth, MD, presents the case of a 60-year-old man with RET+ metastatic medullary thyroid cancer.
Luhua Wang, MD, discussed the impact that the approval of the CAR T-cell therapy brexucabtagene autoleucel has had on mantle cell lymphoma.
Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.
Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.
Solange Peters, MD, PhD, the president of the European Society of Medical Oncology, discusses the use of immunotherapy for the treatment of mesothelioma.
An expert breaks down therapy sequencing in metastatic colorectal cancer and provides some clinical pearls.
Kanwal Raghav, MBBS, MD, explains the rationale for using regorafenib for metastatic colorectal cancer and reviews data from 2 clinical trials.
An oncologist reviews the maintenance therapy options in metastatic colorectal cancer and what clinical findings can lead to a change in therapies.
Kanwal Raghav, MBBS, MD, presents the case of a 72-year-old woman with metastatic colorectal cancer and describes the first-line therapy options.
Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Jason Westin, MD, discusses the current standard of care in diffuse large B-cell lymphoma.
Krina K. Patel, MD, MSc, discusses how she chooses treatment for her patients with early or late relapsed/refractory multiple myeloma.
PARP inhibitors are a common treatment for ovarian cancer, but mechanisms of resistance have yet to be fully understood.
Marcia Brose, MD, discusses the efficacy and safety data of a phase 2 trial examining lenvatinib dose reductions in patients with RAI-DTC.